Latest Comments

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

NICE: too nice for too long?

NICE: too nice for too long?

Samsung’s move towards pharmaceuticals is paying off

Samsung’s move towards pharmaceuticals is paying off

Will lampalizumab finally provide a treatment for macular degeneration?

Will lampalizumab finally provide a treatment for macular degeneration?

Gilead looks to maintain dominance in HIV with its novel STR

Gilead looks to maintain dominance in HIV with its novel STR

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

The NHS hopes that data and the ‘model hospital’ will save it money

The NHS hopes that data and the ‘model hospital’ will save it money

Hemophilia gene therapies impress, but pricing doubts remain

Hemophilia gene therapies impress, but pricing doubts remain

Nestling in: food giant makes its mark on the healthcare industry

Nestling in: food giant makes its mark on the healthcare industry

Merck’s Keytruda stumbles in multiple myeloma

Merck’s Keytruda stumbles in multiple myeloma

Novel Approaches to US Cancer Research Funding on the Horizon

Novel Approaches to US Cancer Research Funding on the Horizon

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

FDA’s New Price-Tackling Strategy Puts Pressure on the Pharmaceutical Industry

Samsung Bioepis emerging as strong player in the Autoimmune space

Samsung Bioepis emerging as strong player in the Autoimmune space

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: BCl-2 as an Emerging Target for AML

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: New Hope for Multiple Myeloma Patients

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Novartis is Leading the CAR-T Cell Race

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EHA 2017: Targeting the Metabolic Control of the Epigenetic Machinery in R/R AML

EULAR 2017: Considerations after first TNF-failure in RA

EULAR 2017: Considerations after first TNF-failure in RA

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

Pharmaxis’ Bronchitol gears up for new drug application after meeting primary endpoint in phase III trial

The anti-vaccination movement and public health

The anti-vaccination movement and public health

Could it be third time lucky for Advair copycats?

Could it be third time lucky for Advair copycats?